Enhancing Management Algorithms for Children Conceived Via Assisted Reproductive Technologies

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age0-3
SponsorKazakhstan's Medical University "KSPH"

About this trial

Research Methods and Ethical Issues

1. Main Scientific Questions and Hypotheses of the Project The primary objective of this project is to investigate the impact of advanced ART methods on the health status of children. The central scientific questions being addressed include: What are the consequences of ICSI and FET on the physical, cognitive, and reproductive health of children? The underlying hypothesis posits that children conceived by advanced ART methods may present with health indicators that deviate from the established norms. 2. Description of the Experiments

Research Methods:

To achieve the goals of the study, the following stages are anticipated:

1. Retrospective Analysis of Anamnestic Data:

This stage involves studying the relationship between the physical status and morbidity structure of 300 children under the age of three, who were conceived by advanced ART methods. Additionally, the medical history of their mothers regarding the use of various medications during pregnancy-such as estrogen, progesterone, thyroid hormones, antithyroid hormones, vitamins, microelements, and aspirin-will be examined. To facilitate this analysis, individual registration cards will be developed, approved by the ethics committee, and ratified by the Academic Council. The data will be submitted using Google Forms, followed by the inclusion of copyright information into the state register. 2. Evaluation of Anthropometric Data:

This stage will assess the anthropometric data of 300 children under three years of age, focusing on those born after FET or fresh embryo transfer (Fresh-ET). Measurements will include weight, height, and head and chest circumference at the time of examination. Measurements for children under one year will utilize scales with a pan balance, a horizontal stadiometer, and a measuring tape. For children over one year, floor electronic scales, a vertical stadiometer, and a centimeter tape will be employed. Birth anthropometric data will be sourced retrospectively, while the WHO Child Growth Standards will be utilized to evaluate weight, height, head, and chest circumference relative to age and gender. 3. Study of Psychomotor Development:

The psychomotor development of the 300 children under three years of age conceived via IVF or ICSI in fresh or frozen cycles will be assessed. This evaluation will employ standardized instruments such as the R. Griffiths Mental Development Scale and Denver Developmental Screening Tests. For children under one year, neurosonography will be conducted to assess brain structures, and retrospective results for children over one year of age will be extracted from medical records.

The assessment aims to determine the functions of the nervous system utilizing the aforementioned standardized scales, focusing on various developmental parameters, including motor skills, social adaptation, communication abilities, and play skills. Scores will be compiled to ascertain overall developmental levels. The Denver II developmental screening test is specifically designed to assess children from birth to six years of age. It enhances diagnostic capabilities and evaluates several critical parameters, including: 1) personal and social characteristics, which examine the child's interactions with others and their ability to meet personal needs; 2) the development of gross and fine motor skills; 3) the development of both motor and sensory speech; and 4) an assessment of the child's behavior during the evaluation process.

In cases where children are identified as being in the "risk group," a consultation with a neurologist is planned to establish examination protocols and identify the etiopathogenetic basis for potential developmental disorders. Standard methods of neurological examination will be utilized to assess the development of motor, sensory, cognitive, speech, emotional, communicative, and behavioral parameters in conjunction with anamnestic data and the overall state of somatic health. 4. Assessment of Reproductive Health:

The study will also evaluate the effect of ICSI, particularly in cases of male infertility, on the reproductive health and development of 200 male children under three years of age, in comparison with children conceived via classic IVF. This evaluation will involve objective examinations conducted by a pediatric andrologist to investigate the prevalence of urogenital pathology, supplemented by ultrasounds of the scrotum, kidneys, and bladder. Additionally, hormonal status will be assessed by Inhibin B and Anti-Müllerian Hormone (AMH). Anamnestic data will be collected to explore the relationship between the reproductive health of fathers and their sons born after ICSI.

3\) Methods of Data Collection and Processing Data Collection Sources of Information: Data will be sourced from the International clinical center of the reproductology "PERSONA" and Institute of Reproductive Medicine (IRM clinic), in addition to direct examinations of participants based

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Born as a result of an ART program (IVF, ICSI, FET, or Fresh-ET).

Age at the time of assessment: from birth up to 36 months.

Availability of complete perinatal and medical documentation, including ART cycle characteristics and neonatal outcomes.

Informed consent provided by parents or legal guardians for participation in the study and for biological sample collection (where applicable).

Disqualifiers

None

Trial population

The study population will consist of children under three years of age who were conceived via assisted reproductive technologies (ART) in the Republic of Kazakhstan, along with their biological parents. The research cohort will include children conceived through advanced ART methods - specifically intracytoplasmic sperm injection (ICSI) and frozen embryo transfer (FET) - as well as a comparison group of children conceived via conventional IVF and fresh embryo transfer (Fresh-ET). A total of approximately 300 children (including at least 200 male participants for reproductive health analysis) will be recruited from reproductive medicine centers, pediatric hospitals, and outpatient clinics across Kazakhstan. Medical records of participating mothers will also be used for retrospective data collection regarding conception details, pregnancy course, and perinatal outcomes.

Trial design

Design model

Cohort

Time perspective

Cross-sectional

Treatments tested in this trial

  • Inhibin B

    Diagnostic test

    The study will also evaluate the effect of ICSI, particularly in cases of male infertility, on the reproductive health and development of 200 male children under three years of age, in comparison with children conceived via classic IVF. This evaluation will involve objective examinations conducted by a pediatric andrologist to investigate the prevalence of urogenital pathology, supplemented by ultrasounds of the scrotum, kidneys, and bladder. Additionally, hormonal status will be assessed by Inhibin B and Anti-Müllerian Hormone (AMH). Anamnestic data will be collected to explore the relationship between the reproductive health of fathers and their sons born after ICSI.

  • Anti-Müllerian Hormone (AMH)

    Diagnostic test

    The study will also evaluate the effect of ICSI, particularly in cases of male infertility, on the reproductive health and development of 200 male children under three years of age, in comparison with children conceived via classic IVF. This evaluation will involve objective examinations conducted by a pediatric andrologist to investigate the prevalence of urogenital pathology, supplemented by ultrasounds of the scrotum, kidneys, and bladder. Additionally, hormonal status will be assessed by Inhibin B and Anti-Müllerian Hormone (AMH). Anamnestic data will be collected to explore the relationship between the reproductive health of fathers and their sons born after ICSI.

Treatment groups

300 Participants
are divided into 2 treatment groups
Group A: children born after ICSI2 interventions
Group B: children born after IVF2 interventions

Trial outcomes

Primary outcomes

1

Physical growth parameters of children conceived via ART (ICSI and FET)

Evaluation of physical growth using standardized anthropometric measures: weight (kg), length/height (cm), and head circumference (cm), assessed against WHO Child Growth Standards. Unit of Measure: Z-scores (weight-for-age, length-for-age, head-circumference-for-age).

Time frame
At birth (medical records) and at clinical assessment conducted at the child's age at enrollment (up to 36 months of age).
2

Psychomotor and neurodevelopmental status of children conceived via ART (ICSI and FET)

Assessment of cognitive, motor, language, and social-emotional development using the Bayley Scales of Infant and Toddler Development, Fourth Edition (Bayley-IV). Scores range from 40 to 160; higher scores indicate better developmental performance. Unit of Measure: Bayley-IV composite scores (Cognitive, Motor, Language).

Time frame
At a single clinical assessment conducted at the child's age at enrollment (up to 36 months of age).
3

Urogenital and reproductive system development in children conceived via ART (ICSI and FET)

Clinical examination and ultrasonographic assessment of urogenital system development performed by pediatric urologists/gynecologists. Parameters include presence or absence of congenital anomalies (e.g., cryptorchidism, hypospadias), uterus/ovary/testis morphology, and developmental measurements as per pediatric normative standards. Unit of Measure: Incidence of anomalies (yes/no), organ measurements (mm).

Time frame
At a single clinical assessment conducted at the child's age at enrollment (up to 36 months of age).

Secondary outcomes

1

Weight-for-Age Z-Score

Assessment of somatic growth using WHO Child Growth Standards.

Time frame
At birth (medical records) and at clinical assessment conducted at the child's age at enrollment (up to 36 months of age).
2

Height-for-Age Z-Score

Evaluation of linear growth relative to age-specific WHO standards.

Time frame
At birth (medical records) and at clinical assessment conducted at the child's age at enrollment (up to 36 months of age).
3

Head Circumference-for-Age Z-Score

Measurement of head growth relative to WHO Child Growth Standards.

Time frame
At birth (medical records) and at clinical assessment conducted at the child's age at enrollment (up to 36 months of age).
4

Psychomotor development score (Griffiths Scales)

Global developmental assessment using the Griffiths Mental Development Scales, including motor, communication, social, and cognitive domains. Assessment Tool: Griffiths Mental Development Scales (GMDS). Range: Developmental Quotient (DQ), typically 0-130; higher scores indicate better developmental performance. Unit of Measure: Griffiths DQ Composite Score.

Time frame
At a single clinical assessment conducted at the child's age at enrollment (up to 36 months of age).

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Kazakhstan's Medical University "KSPH"

Lead sponsor

International Clinical Center for Reproductology "PERSONA"

Collaborator